Pfizer: drug reduces rare disease death risk
(CercleFinance.com) - Pfizer said its Tafamidis experimental drug reduced the risk of mortality by 30% in people with transthyretin amyloid cardiomyopathy, a rare disease, versus placebo in a late-stage trial.
The phase 3 study also showed that tafamidis reduced the frequency of cardiovascular-related hospitalizations compared to placebo over a 30-month period by 32%, the US drugmaker said.
Transthyretin amyloid cardiomyopathy is a rare, fatal, and underdiagnosed condition associated with progressive heart failure, for which there are currently no approved pharmacologic treatments.
The findings were presented at the ESC Congress 2018 in Munich, Germany and simultaneously published online in the New England Journal of Medicine.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The phase 3 study also showed that tafamidis reduced the frequency of cardiovascular-related hospitalizations compared to placebo over a 30-month period by 32%, the US drugmaker said.
Transthyretin amyloid cardiomyopathy is a rare, fatal, and underdiagnosed condition associated with progressive heart failure, for which there are currently no approved pharmacologic treatments.
The findings were presented at the ESC Congress 2018 in Munich, Germany and simultaneously published online in the New England Journal of Medicine.
Copyright (c) 2018 CercleFinance.com. All rights reserved.